Hypothesis

NAD+ decline does not merely reflect a passive metabolic downturn; it actively drives the suppression of HAS2 and the shift toward proinflammatory low-molecular-weight hyaluronan (LMW-HA) in aged dermis by attenuating NAD+-dependent sirtuin activity, which in turn lifts inhibitory brakes on NF-κB signaling and microRNA-23a-3p-mediated HAS2 repression.

Mechanistic Model

1. ECM damage → collagen fragments (from MMP cleavage) suppress HAS2 transcription 1.
2. Collagen fragments also sustain NF-κB activation via TLR2/4/CD44, generating LMW-HA that acts as a DAMP 3.
3. In youthful cells, high NAD+ fuels SIRT1 and SIRT6 deacetylase activity:
   • SIRT1 deacetylates NF-κB p65, reducing its transcriptional potency.
   • SIRT6 deacetylates histone H3K9 at the HAS2 promoter, maintaining an open chromatin state.
   • Both sirtuins repress the transcription of miR-23a-3p, a microRNA that directly targets HAS2 mRNA for degradation.
4. With age, NAD+ falls, sirtuin activity wanes, leading to:
   • Hyperacetylated NF-κB → increased transcription of proinflammatory cytokines and miR-23a-3p.
   • Loss of promoter acetylation → chromatin compaction at HAS2.
   • Elevated miR-23a-3p → post-transcriptional silencing of HAS2.
5. The net result is reduced HMW-HA synthesis, accumulation of LMW-HA, and a self-reinforcing inflammatory loop.

Testable Predictions

• Restoring NAD+ in aged dermal fibroblasts will increase SIRT1/6 activity, decrease NF-κB acetylation, lower miR-23a-3p levels, and rescue HAS2 expression and HMW-HA secretion even when collagen fragments are present.
• Pharmacologic inhibition of SIRT1 or SIRT6 will abolish the rescue effect of NAD+ supplementation.
• Overexpression of a deacetylation-deficient SIRT mutant will mimic the aged phenotype despite high NAD+.

Experimental Approach

1. Culture primary human dermal fibroblasts from young and old donors.
2. Treat with collagen-derived peptides to mimic ECM damage.
3. Add NAD+ precursor (nicotinamide riboside, NR) ± SIRT1 inhibitor (EX-527) or SIRT6 inhibitor (MDL-801).
4. Measure:
   • NAD+ levels (enzymatic assay).
   • SIRT1/6 activity (fluorometric deacetylase assay).
   • NF-κB p65 acetylation (Western blot with acetyl-lysine antibody).
   • miR-23a-3p levels (qRT-PCR).
   • HAS2 mRNA and protein (qRT-PCR, Western).
   • HA size distribution (agarose gel electrophoresis + HA-binding protein probe).
   • Secreted HMW-HA vs LMW-HA (ELISA with size-specific antibodies).
5. Include controls: vehicle, NR alone, inhibitors alone.

Potential Outcomes and Falsifiability

• Supportive outcome: NR treatment restores HMW-HA, reduces LMW-HA, lowers NF-κB acetylation and miR-23a-3p, and increases HAS2 despite collagen fragments; these effects are blocked by SIRT1/6 inhibition.
• Falsifying outcome: NR fails to raise HAS2 or shift HA size spectrum, or SIRT inhibition does not affect NR’s action, indicating NAD+ acts independently of sirtuins in this context.

This hypothesis positions NAD+-sirtuin signaling as a regulatory rheostat that translates metabolic state into ECM homeostasis, offering a mechanistic bridge between the ‘budget cut’ idea of NAD+ decline and the damage-driven suppression of HAS2 outlined in the seed literature.